Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
iscalimab - CD40 inhibitor
Study
Indication
Phase
NCT03781414 CONTRAIL I (CCFZ533A2202)
Liver transplantation
Phase 2
Patients
128
NCT03905525 TWINSS (CCFZ533B2201)
Sjögren's syndrome
Phase 2
260
Primary Outcome
Measures
Arms Intervention
Proportion of patients with composite event (BPAR, Graft Loss or Death) over 12
months
Control/Standard of Care: TAC + MMF + Corticosteroids
CFZ533 dose A+ MMF + Corticosteroids
CFZ533 dose B + MMF + Corticosteroids
Liver transplant recipients
Change in EULAR Sjögren's syndrome Disease Activity Index (ESSDAI) score and
EULAR Sjögren's syndrome Patient Reported Index (ESSPRI) score
Three dose arms of CFZ533
Placebo
Target Patients
Read-out Milestone(s)
2023
Publication
2023
86 Investor Relations | Q4 2021 Results
Patients with Sjögren's syndrome
2022
2022
NOVARTIS | Reimagining MedicineView entire presentation